Please login to the form below

Zaltrap

This page shows the latest Zaltrap news and features for those working in and with pharma, biotech and healthcare.

Rise in cancer therapy costs 'unsustainable' says oncologist

Saltz has been a vocal critic of cancer drug pricing for some time, and was one of the architects of MSKCC's decision three years ago not to prescribe Zaltrap ... Zaltrap was also turned down by the UK's National Institute for Health and Care Excellence

Latest news

England's Cancer Drugs Fund: Fixing a broken system

One of these has been Sanofi, whose prostate cancer drug Jevtana (cabazitaxel) and bowel cancer medicine Zaltrap (aflibercept) were deemed too expensive for both the specialist CDF and for NICE. ... Sanofi's Zaltrap (aflibercept):. second line treatment
Pharma condemns Cancer Drugs Fund cuts

Sanofi's Zaltrap is one of several drugs to be delisted from England's Cancer Drugs Fund. ... cancer. In the past 18 months there have been 1, 154 and 707 requests submitted to the CDF for Zaltrap and Jevtana respectively.
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Prostate cancer. Zaltrap (aflibercept). Colorectal cancer. Takeda. Adcetris (brentuximab vedotin). Lymphoma (3 indications).
Charity demands action on cancer drug prices in UK

Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
England's Cancer Drugs Fund: Naughty or NICE?

Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).

More from news
Approximately 5 fully matching, plus 18 partially matching documents found.

Latest Intelligence

The reality of real-world evidence

Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Medical Writer: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Project Manager, Medical Communications, Oxford: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager – Med Comms – London: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Project Manager, Medical Communications, London: Excellent Salary

Scientific Director: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editor – Medical Education Agency – Bucks: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Account Manager / Account Director: Great salary and bebefits

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Programme Executive: Salary TBC

Medical Writer, e-learning/ training, London: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Subscribe to our email news alerts

PMHub

Add my company

PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...